Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: A propensity score analysis using a nationwide administrative database

Pancreas

Volumn 42, Issue 2, 2013, Pages 260-264

  Yasunaga, Hideo ^a   Horiguchi, Hiromasa ^a   Hashimoto, Hideki ^b   Matsuda, Shinya ^c   Fushimi, Kiyohide ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

acute pancreatitis; gabexate mesylate; propensity score analysis; protease inhibitor

Indexed keywords

GABEXATE MESILATE;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; CHI-SQUARE DISTRIBUTION; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GABEXATE; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; JAPAN; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PANCREATITIS; PROPENSITY SCORE; SERINE PROTEINASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874115215     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31826495a0     Document Type: Article

References (26)

1. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008; 371:143-152.
2. Whitcomb DC. Acute pancreatitis. New Engl J Med. 2006;354: 2142-2150.
3. Kingsnorth A, O'Reilly D. Acute pancreatitis. BMJ. 2006;332:1072-1076.
4. Bang UC, Semb S, Nojgaard C, et al. Pharmacological approach to acute pancreatitis. World J Gastroenterol. 2008;14:2968-2976.
5. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698-700.
6. Valderrama R, Perez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65-70.
7. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993;104:1165-1170.
8. Chen HM, Chen JC, Hwang TL, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47:1147-1150.
9. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. Gut. 2005;54(suppl 3):iii1-iii9.
10. Pelagotti F, Cecchi M, Messori A. Use of gabexate mesylate in Italian hospitals: A multicentre observational study. J Clin Pharm Ther. 2003;28:191-196.
11. Pezzilli R, Zerbi A, Di Carlo V, et al. Practical guidelines for acute pancreatitis. Pancreatology. 2010;10:523-535.
12. Takeda K, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute pancreatitis: Medical management of acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13:42-47.
13. Satoh K, Shimosegawa T, Masamune A, et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2011;40:503-507.
14. Matsuda S, Ishikawa KB, Kuwabara K, et al. Development and use of the Japanese case-mix system. Eurohealth. 2009;14:27-30.
15. Ueda T, Takeyama Y, Yasuda T, et al. Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. J Gastroenterol. 2009;44:453-459.
16. Takeda K, Yokoe M, Takada T, et al. Assessment of severity of acute pancreatitis according to new prognostic factors and CT grading. J Hepatobiliary Pancreat Sci. 2010;17:37-44.
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
18. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33-38.
19. Landrum MB, Ayanian JZ. Causal effect of ambulatory specialty care on mortality following myocardial infarction: A comparison of propensity score and instrumental variable analyses. Health Serv Outcomes Res Methods. 2001;2:221-245.
20. Ayanian JZ, Landrum MB, Guadagnoli E, et al. Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction. N Engl J Med. 2002;347:1678-1686.
21. Wisner JR Jr, Renner IG, Grendell JH, et al. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas. 1987;2:181-186.
22. Piavcik M, Rydzewska G, Milewski J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: A randomized controlled study. Pancreas. 2010;39:863-867.
23. Petrov MS, van Santvoort HC, Besselink MG, et al. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: A meta-analysis of randomized trials. Arch Surg. 2008;143:1111-1117.
24. Jafri NS, Mahid SS, Idstein SR, et al. Antibiotic prophylaxis is not protective in severe acute pancreatitis: A systematic review and meta-analysis. Am J Surg. 2009;197:806-813.
25. OECD. OECD Health Data 2011. Paris, France: Organisation for Economic Co-operation and Development; 2011.
26. Hashimoto H, Ikegami N, Shibuya K, et al. Cost containment and quality of care in Japan: Is there a trade-off? Lancet 2011;378:1174-1182.